Pharmacogenomic Contributions to Trihexyphenidyl Biotransformation and Response in Children With Dystonic Cerebral Palsy
Part of paid clinical trials in Kansas City, Missouri.
- Sponsor
- Children's Mercy Hospital Kansas City
- Study ID
- NCT06554288
- Phase
- PHASE1
- Status
- Recruiting
Conditions
- Cerebral Palsy, Dyskinetic
- Cerebral Palsy, Dystonic-Rigid
- Dystonia
- Dystonia, Secondary
- Genetic Predisposition
- Pediatric Disorder
- Pharmacogenomic Drug Interaction
- Trihexyphenidyl Adverse Reaction
Eligibility Criteria
- Sex
- ALL
- Age
- 5 Years - 17 Years
- Healthy Volunteers
- Not accepted
Interventions
- Trihexyphenidyl — DRUG6-week dose escalation up to 0.25mg/kg TID, followed by a 9-week maintenance period at this dose
Study Details
This study looks at how a medicine called trihexyphenidyl works in children with dystonic cerebral palsy. The study aims to understand how trihexyphenidyl is broken down and used in the body of pediatric patients and whether this is impacted by a person's genetics. Information from this study will also be used to design future clinical trials.
Key Dates
- Start date
- Oct 15, 2024
- Status verified
- Jul 2025
- Primary completion
- Nov 30, 2029
- Completion
- Dec 31, 2029
Study Design
- Enrollment
- 40 participants (estimated)
- Allocation
- NA
- Intervention model
- SINGLE_GROUP
- Primary purpose
- TREATMENT
Arms
- Experimental: TrihexyphenidylParticipants receive trihexyphenidyl following the dose escalation schedule below: Week 1: 0.05 mg/kg BID Week 2: 0.05 mg/kg TID Week 3: 0.1 mg/kg TID Week 4: 0.15 mg/kg TID Week 5: 0.20 mg/kg TID Week 6-15: 0.25 mg/kg TID
Primary Outcome Measure
Difference in Cmax between CYP2D6 and CYP2C19 phenotype groups [ Time Frame: Baseline ]
Central Contacts
- Rose Gelineau-Morel, MD816-302-3331
- Rachel Nass8166011354
Locations (1)
| Facility | City | State | ZIP | Site coordinators |
|---|---|---|---|---|
| Children's Mercy Hospital Kansas City | Kansas City | Missouri | 64108 | Rose Gelineau-Morel, MD (PRINCIPAL_INVESTIGATOR) |
Find similar trials in Kansas City, MO
By research site
Related Studies
- Clinical Outcomes for Deep Brain StimulationRecruiting · Washington University School of Medicine · St Louis, Missouri
- APOL1 Genetic Testing in African AmericansRecruiting · St. Louis University · St Louis, Missouri
- A Study to Evaluate the Efficacy, Safety, and Tolerability of VIM0423 in Individuals With Isolated DystoniaPHASE2 · Recruiting · Vima Therapeutics · Birmingham, Alabama
- Physiological Brain Atlas DevelopmentRecruiting · Vanderbilt University Medical Center · Nashville, Tennessee